Gilead and Roche are continuing to lay off employees in California, with each company revealing a recent round of cuts through the state’s Worker Adjustment and Retraining Notification (WARN) program. While Gilead is eliminating 149 positions at its headquarters in
read moreLast year, AbbVie’s Skyrizi and Rinvoq were practically unshakeable atop the monthly TV drug ad spending rankings, ultimately leading the pair of immunology meds to take the full-year title for the third year in a row. 2025, however, is already
read moreViatris has agreed to a settlement worth up to $335 million to resolve opioid-related claims to state and local governments. More: Viatris agrees to pay up to 5M to settle opioid claims Source: fierce
read more
Research targets lysosomal function restoration for neurodegeneration More: Endlyz Therapeutics emerges with pipeline for Parkinson’s disease Source: News
read moreOn the heels of a recent cost-cutting drive that severed much of AmplifyBio’s R&D capacity, the Ohio-based contract manufacturing and research hybrid has hung up its hat for good. The company attributed the decision to a downturn in the market
read more
The Scottish Medicines Consortium (SMC) has approved bimekizumab for adults with active moderate to severe hidradenitis suppurativa (HS) who have not responded to conventional systemic therapies. This approval makes Scotland the first country in the UK to offer bimekizumab for
read more© 1994 - 2026 B.M. Pharmaceuticals